Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:epacadostat
|
| gptkbp:ATCCode |
none (not assigned)
|
| gptkbp:CASNumber |
1204669-58-8
|
| gptkbp:chemicalFormula |
C11H13BrFN7O4
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2018)
|
| gptkbp:developedBy |
gptkb:Incyte_Corporation
|
| gptkbp:failedTrial |
ECHO-301/KEYNOTE-252 (melanoma)
|
| https://www.w3.org/2000/01/rdf-schema#label |
INCB024360
|
| gptkbp:intendedUse |
immunotherapy
|
| gptkbp:mechanismOfAction |
IDO1 inhibitor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105728
46216763 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
INCB-24360
INCB24360 |
| gptkbp:target |
indoleamine 2,3-dioxygenase 1 (IDO1)
|
| gptkbp:UNII |
6QX8J8QK0E
|
| gptkbp:bfsParent |
gptkb:epacadostat
|
| gptkbp:bfsLayer |
8
|